Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022
Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally...
Source: prnewswire.com